CN114468196A

CN114468196A - Compound multivitamin coenzyme Q10 effervescent tablet and preparation method thereof

Info

Publication number: CN114468196A
Application number: CN202210199609.0A
Authority: CN
Inventors: 许子华; 赵庆春; 陈莹; 王泽星; 胡北; 马群
Original assignee: General Hospital of Shenyang Military Region
Current assignee: General Hospital of Shenyang Military Region
Priority date: 2022-03-02
Filing date: 2022-03-02
Publication date: 2022-05-13

Abstract

The invention relates to a compound multivitamin coenzyme Q10 effervescent tablet and a preparation method thereof, wherein the effervescent tablet comprises the following components: raw materials, an acid source and an alkali source, a sweetening agent, a lubricating agent, a filling agent, a binding agent, essence and polysorbate-80; the raw materials comprise, by weight, 105 parts of coenzyme Q, 5 parts of vitamin C, 2.5 parts of nicotinamide, 60.5 parts of vitamin B, 1.5 parts of potassium citrate and 0.5 part of zinc gluconate. The invention firstly proposes to develop a compound preparation which is rich in coenzyme Q10, multiple vitamins, electrolytes, energy and other nutrient substances needed by organisms, and the novel preparation has the advantages of good administration compliance, convenient carrying, rapid absorption, high bioavailability, good taste and the like. The product has effects in improving energy supply, inhibiting active oxygen generation, nourishing myocardium, and relieving exercise fatigue.

Description

Compound multivitamin coenzyme Q10 effervescent tablet and preparation method thereof

Technical Field

The invention relates to the technical field of health-care food, in particular to a compound multivitamin coenzyme Q10 effervescent tablet and a preparation method thereof.

Background

No matter whether athletes or ordinary body builders, when doing high-intensity exercises or training, the problems of physical energy consumption, body fatigue, heart load aggravation and the like are faced, and simultaneously, the loss and the loss of vitamins, electrolytes, energy and the like of the body are caused. Therefore, there is an urgent need for a sports health and anti-fatigue preparation which can rapidly relieve fatigue, nourish cardiac muscle, specifically supplement essential nutrients lost by the body, solve the problem of energy and nutrition supplementation after a large amount of physical energy consumption or physical energy exhaustion during sports or training, reduce the occurrence of cardiac risk events, and relieve motility.

Disclosure of Invention

The purpose of the invention is as follows: the invention provides a compound multi-dimensional coenzyme Q10 effervescent tablet and a preparation method thereof, and aims to solve the problems of energy and nutrition supplement after a large amount of physical energy is consumed or the physical energy is exhausted in the process of officer and soldier high-intensity combat and training of troops.

The technical scheme is as follows:

a compound multivitamin coenzyme Q10 effervescent tablet comprises the following components in percentage by mass:

the raw materials comprise, by weight, 105 parts of coenzyme Q, 5 parts of vitamin C, 2.5 parts of nicotinamide, 60.5 parts of vitamin B, 1.5 parts of potassium citrate and 0.5 part of zinc gluconate.

Preferably, the filler is lactose; the adhesive is PVP K30; the sweetener is stevioside; the lubricant is PEG 6000.

Preferably, the alkali source is sodium bicarbonate, the acid source is tartaric acid, and the mass ratio of the tartaric acid to the sodium bicarbonate is 1-1.2: 1.

A preparation method of compound multivitamin coenzyme Q10 effervescent tablets comprises the steps of mixing vitamin C, nicotinamide, vitamin B6, potassium citrate, zinc gluconate, an acid source, half of a filling agent, a bonding agent and a sweetening agent in percentage by mass according to parts by weight, sieving with a 20-mesh sieve, granulating, drying, and preparing into acid granules; mixing coenzyme Q10 and polysorbate-80 in percentage by mass, grinding uniformly, adding an alkali source and half of filler, adhesive and sweetener in percentage by mass, sieving with a 20-mesh sieve, granulating, and drying to obtain alkali granules; mixing the acid granules and the alkali granules, adding the pigment and the lubricant according to the mass percentage, uniformly mixing, sieving with a 20-mesh sieve, granulating and tabletting.

Has the advantages that: the invention firstly proposes to develop a compound preparation rich in coenzyme Q10, multiple vitamins, electrolytes, energy and other nutrients required by organisms, and the novel preparation has the advantages of good administration compliance, convenient carrying, rapid absorption, high bioavailability, good taste and the like. The product has effects in improving energy supply, inhibiting active oxygen generation, nourishing myocardium, and relieving exercise fatigue.

Drawings

Figure 1 is the effect of the acid-base ratio of the effervescent disintegrant on pH;

FIG. 2 is an A-B response surface plot and a contour plot;

FIG. 3 is an A-C response surface plot and a contour plot;

FIG. 4 is a B-C response surface plot and a contour plot;

FIG. 5 shows experimental results of experimental behavioural tests of weight swimming of mice;

FIG. 6 shows experimental behavioural test results of the grip strength of the forelimb of a mouse;

FIG. 7 shows the experimental results of mouse rod rotation;

FIG. 8 shows the experimental results of the mouse climbing rod experiment;

FIG. 9 is the level of MDA in mouse serum;

FIG. 10 is the level of SOD in mouse serum;

FIG. 11 is the level of LD in mouse serum;

FIG. 12 is the level of BUN in mouse serum;

FIG. 13 is the level of mouse liver glycogen;

FIG. 14 is HE staining;

FIG. 15 is reverse transcription-real-time fluorescence quantitative PCR;

FIG. 16 Effect of AMPK, p-AMPKP, GC-1. alpha. protein expression in gastrocnemius muscle after mouse exercise;

FIG. 17 Effect of Bcl-2, Bax protein expression in gastrocnemius muscle after exercise in mice.

Detailed Description

The invention is described in more detail below with reference to the accompanying drawings.

The invention firstly proposes that the coenzyme Q10 and vitamins and the like are combined together, so that the energy is supplemented, the cardiac muscle can be nourished, and the fatigue is relieved. In the preparation process, polysorbate 80 and coenzyme Q10 are added and ground uniformly to play a role in solubilization.

Example 1

The compound multivitamin coenzyme Q10 effervescent tablet comprises 105 parts of coenzyme Q, 5 parts of vitamin C, 2.5 parts of nicotinamide, 60.5 parts of vitamin B, 1.5 parts of potassium citrate and 0.5 part of zinc gluconate, wherein the mass percentages of the raw materials and other components are as follows: 3% of raw materials, 70% of acid source and alkali source, 2% of stevioside, 2% of PEG 60003%, 17% of lactose, 302% of PVP K, 2% of essence and 801% of polysorbate.

The alkali source is sodium bicarbonate, the acid source is tartaric acid, and the mass ratio of the tartaric acid to the sodium bicarbonate is 1.2: 1.

A preparation method of compound multivitamin coenzyme Q10 effervescent tablets comprises the steps of mixing vitamin C, nicotinamide, vitamin B6, potassium citrate, zinc gluconate, an acid source, half of lactose, PVP K30 and stevioside in percentage by weight, sieving with a 20-mesh sieve, granulating, drying, and preparing into acid granules; mixing coenzyme Q10 and polysorbate-80 according to weight parts and mass percentage, grinding uniformly, adding an alkali source, half of lactose, PVP K30 and stevioside according to mass percentage, sieving with a 20-mesh sieve, granulating, drying, and preparing into alkali granules; mixing the acid granules and the alkali granules, adding the pigment and the lubricant according to the mass percentage, uniformly mixing, sieving with a 20-mesh sieve, granulating and tabletting.

Example 2

The compound multivitamin coenzyme Q10 effervescent tablet comprises 105 parts of coenzyme Q, 5 parts of vitamin C, 2.5 parts of nicotinamide, 60.5 parts of vitamin B, 1.5 parts of potassium citrate and 0.5 part of zinc gluconate, wherein the mass percentages of the raw materials and other components are as follows: 5% of raw materials, 60% of acid source and alkali source, 3% of stevioside, PEG 60004%, 22.5% of lactose, 302% of PVP K, 2% of essence and 801.5% of polysorbate.

The alkali source is sodium bicarbonate, the acid source is tartaric acid, and the mass ratio of the tartaric acid to the sodium bicarbonate is 1.1: 1.

Example 3

The compound multivitamin coenzyme Q10 effervescent tablet comprises 105 parts of coenzyme Q, 5 parts of vitamin C, 2.5 parts of nicotinamide, 60.5 parts of vitamin B, 1.5 parts of potassium citrate and 0.5 part of zinc gluconate, wherein the mass percentages of the raw materials and other components are as follows: 1% of raw materials, 75% of acid source and alkali source, 1% of stevioside, PEG 60002%, 18.5% of lactose, 301% of PVP K, 1% of essence and-800.5% of polysorbate.

The alkali source is sodium bicarbonate, the acid source is tartaric acid, and the mass ratio of the tartaric acid to the sodium bicarbonate is 1: 1.

In the raw materials of the invention, the raw materials,

coenzyme Q10: scavenging free radicals, resisting oxidation, protecting heart, relieving fatigue, and enhancing immunity.

Vitamin C: promoting collagen synthesis, resisting oxidation, and improving immunity.

Nicotinamide: is a component of coenzyme I and coenzyme II, becomes a coenzyme of a plurality of dehydrogenases, participates in biological oxidation, and has the function of whitening skin.

Vitamin B6: the blood glucose concentration is kept stable during exercise, smooth glucose catabolism is guaranteed, exercise hypoglycemia is prevented, concentration of pyruvic acid in muscle cells is prevented from rising, lactic acid is reduced, and fatigue caused by exercise is delayed.

Potassium citrate: maintaining normal excitability of cardiac and neuromuscular.

Zinc gluconate: promote the synthesis of nucleic acid, protein and carbohydrate.

The main medicines supplement each other, can specifically supplement essential nutrient components lost by the body, solve the problems of energy and nutrition supplement after a large amount of physical energy consumption or physical energy exhaustion in the process of sports or training, and relieve exercise-induced fatigue.

The determination of the filler and the adhesive the filler is of various types, such as lactose, sucrose, aspartame, mannitol and the like, and mainly plays a role in protecting materials and increasing the volume. The adhesive plays a role in shaping in the granulating process, can strengthen the combination among particles, and is commonly starch slurry, PVP K30, Arabic gum slurry, microcrystalline cellulose and the like. The filler can be starch, dextrin, lactose, sucrose, mannitol and the like, the starch and the dextrin have poor water solubility, the sucrose is easy to absorb moisture, the mannitol has high cost, the lactose has no hygroscopicity, the solution is clear, and the compressibility is good, so the preferable filler is the lactose; the adhesive is PVP K30, an absolute ethyl alcohol solution of 5% PVP K30 is adopted, agglomeration is not prone to occurring in the granulating process, and drying is rapid; the sweetener is stevioside; the lubricant is PEG 6000; the essence can be any existing flavor essence, such as sweet orange essence and the like.

The acid-base ratio of the effervescent disintegrant is determined, sodium bicarbonate is usually selected as an alkali source of the effervescent disintegrant, citric acid and tartaric acid are more common acid sources, the citric acid is extremely easy to absorb moisture, the humidity needs to be strictly controlled, the citric acid is easy to be adhered and washed, the tartaric acid is relatively stable, and the requirement on the environment is not high, so that the tartaric acid and the sodium bicarbonate are respectively selected as the acid source and the alkali source. The adding amount of the effervescent disintegrant is 70%, the stevioside is 2.0%, the PEG6000 is 4%, the sweet orange essence is 1%, the balance is lactose, the mass ratios of tartaric acid and sodium bicarbonate are respectively 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1 and 1.3:1, and the acid-base ratio of the effervescent disintegrant is screened by taking the PH, the disintegration time limit and the mouth feel as indexes. When the proportion of sodium bicarbonate is high, the taste is astringent, the proportion of tartaric acid is too large, the pH is low, the taste is sour, and the tablet is easy to be sticky and flushed. As can be seen from Table 1 and FIG. 1, when the mass ratio of tartaric acid to sodium bicarbonate is 1.2:1, the effervescent tablet has good taste, rapid disintegration, and no sticky punch phenomenon.

TABLE 1 test results for acid-base ratio of effervescent disintegrant

Determining the dosage of the effervescent disintegrant, namely, fixing the mass ratio of tartaric acid to alkali to be 1:1, the mass ratio of stevioside to alkali to be 2.0%, PEG6000 to be 4%, the mass ratio of orange essence to be 1% and the mass ratio of the rest to be lactose, and respectively performing tests on the dosages of the effervescent disintegrant to be 50%, 60%, 70%, 80% and 90% to determine the dosage of the effervescent disintegrant. The influence of the dosage of the effervescent disintegrant on the pH is small, and as can be seen from Table 2, when the dosage is 60-80%, the disintegration time of the effervescent tablet is short, so that response surface tests are carried out by selecting the dosages of the effervescent disintegrant to be 60%, 70% and 80%.

Table 2 test results for effervescent disintegrant dosage

The use amount of the sweetening agent is determined, the stevioside is a natural sweetening agent, the sweetness is 200-300 times that of cane sugar, the calorie is far lower than that of cane sugar, and the safety is high, so that the stevioside is selected as the sweetening agent in the experiment and is used for improving the taste of the effervescent tablet. The mass ratio of tartaric acid to alkali is fixed to be 1:1, the dosage of the effervescent disintegrant is 70%, the PEG6000 is 4%, the sweet orange essence is 1%, the balance is lactose, the adding amount of stevioside is respectively 1%, 1.5%, 2%, 2.5% and 3%, and the dosage of the stevioside is determined.

As the addition amount of stevioside was gradually increased, the sweetness of the effervescent tablet was gradually increased, and when the addition amount was 1%, the sweetness was weak, and when the addition amount was 3%, the sweetness was too strong, as can be seen from table 3, when the addition amount was 1.5% to 2.5%, the mouth feel was relatively good, so that the response surface test was performed by selecting the addition amounts of stevioside of 1.5%, 2%, and 2.5%.

TABLE 3 sweetening agent dosage test results

The determination of the dosage of the lubricant can improve the fluidity, so that the surface of the tablet is smooth and flat, otherwise, the problems of sticking, cracking, difficult tabletting and the like can occur. The commonly used lubricant is magnesium stearate, aerosil, PEG6000, etc. PEG6000 has good lubricating property, and after the PEG6000 is dissolved in water, the solution is clear and has no precipitate, so the PEG6000 is selected as the lubricant in the test. The mass ratio of tartaric acid to alkali is fixed to be 1:1, the dosage of the effervescent disintegrant is 70%, the dosage of stevioside is 2.0%, the dosage of the sweet orange essence is 1%, the rest is lactose, the addition amounts of PEG6000 are respectively 1%, 2%, 3%, 4% and 5%, and the dosage of PEG6000 is determined.

When the dosage of PEG6000 is 1%, the surface of the effervescent tablet is not smooth enough and the effervescent tablet is easy to loosen, while when the dosage is 5%, the effervescent tablet is slow to disintegrate and the viscosity is increased, and when the dosage of PEG6000 is 2% -4%, the effervescent tablet is smooth in surface and fast to disintegrate. As can be seen from Table 4, the response surface test was carried out with the amounts of PEG6000 selected at 2%, 3% and 4%.

TABLE 4 Lubricant usage test results

Selecting Box-Behnken to establish a model, taking the dosage of the effervescent disintegrant (A), the dosage of stevioside (B) and the dosage of PEG6000 (C) as evaluation factors, taking sensory score as an evaluation index, and adopting Design-Expert software to perform data processing and analysis. The results are shown in tables 5 and 6.

By regression fitting, a regression equation is established as: y ═ 9.46+0.1875A-0.0750B-0.0375C-0.0750AB-0.0500 AC +0.1750BC-1.16A²-0.7300B²-0.5550C². F-57.02, P of regression model<0.0001, the model is significant. The mismatching term F is 2.37, and P is 0.2114>0.05, which shows that the regression equation fits well. The first term a, the second terms BC and A, B, C have a significant effect on the response values. By comparison of the F values, the three factors influence sensory scores in the order: a. the>B>C。

The steeper the curve, the greater the effect of this factor on the response value, as shown in the response surface plots (fig. 2-4). The curved surfaces of A, B, A and C are steeper, indicating that the use level of the effervescent disintegrant and the stevioside has more obvious influence on the sensory score; the curved surfaces of C and B are relatively flat, which shows that the influence of the dosage of PEG6000 on the sensory score is small.

The parameters are optimized and analyzed to obtain the optimal conditions of 70.8 percent of disintegrant dosage, 2 percent of stevioside and 2 percent of PEG 60003 percent, samples are prepared according to the conditions, process verification is carried out, the measured sensory score is 9.4 and is similar to the predicted value of 9.47, and the conditions are stable and reliable.

TABLE 5 Box-Behnken test results

TABLE 6 results of analysis of variance of response surface model

Note: p <0.05, indicating that the model or the investigation factor has a significant influence; p <0.0001, indicates a very significant effect experiment 1 behavioral test

1.1 Experimental animals

60 KM mice of 4-5 weeks are selected, the mice are clean, and the mice have the weight of 20 +/-2 g and are divided into 5 groups, wherein each group comprises 12 mice, and each half of the mice is a blank group (control), a Low dose group (Low), a Medium dose group (Medium), a High dose group (High) and a Positive drug group (Positive). Supplied by Liaoning Biometrics, Inc. (license number: SCXK (Liao) 2020 + 0001). The breeding temperature is 21-24 ℃, the humidity is 40% -60%, drinking water is freely taken, the environment is adapted, and experiments are carried out after one week.

1.2 mouse weight bearing swimming experiment

The gavage compound multidimensional coenzyme Q10 effervescent tablet is continuously administrated for 30d, the last administration is carried out for 60min, a lead skin load with the mass being 5% of the body mass of a mouse is tied at the tail of the mouse, the mouse is placed in a swimming box with the water depth being 30cm and the water temperature being 30 +/-0.5℃ until the mouse can not float out of the water surface after sinking to the water surface for 8s, and the time (min) from the beginning of swimming to exhaustion is recorded as the weight swimming time of the mouse. The results are shown in FIG. 5. The results show that: the swimming time under load was very significantly prolonged (P < 0.01) in the low dose group compared to the blank group, and prolonged but not significant in the other dose groups.

1.3 mouse forelimb grip Strength test

And (3) gavage compound multi-dimensional coenzyme Q10 effervescent tablets are continuously administrated for 30d, and are administrated for 60min at the last time, and forelimb grip strength is measured. Lifting the tail of the mouse, grabbing the grabbing plate by the front claw, slightly pulling the mouse backwards in parallel with the grabbing plate, automatically reading the maximum value by the instrument, measuring for 3 times, and taking out the average value as the fore limb grabbing value of the mouse. The results are shown in FIG. 6. The results show that: compared with the blank group, the grip strength of the forelimb of the mice in the low-dose group is remarkably increased (P is less than 0.05), and the grip strength of the forelimb of the mice in the medium-high dose group and the positive drug group is remarkably increased (P is less than 0.01).

1.4 mouse rod rotation experiment

The gavage compound multi-dimensional coenzyme Q10 effervescent tablet is continuously administrated for 30d, the last time of administration is 60min, and a fatigue bar rotating experiment with the rotating speed of 30r/min is carried out on a mouse. The adaptive training is carried out on the mouse 3 times before the formal experiment, the falling time of the mouse from the rotating rod is recorded in the formal experiment, the measurement is carried out for 3 times, and the average value is taken as the rotating rod time of the mouse. The results are shown in FIG. 7. The results show that: compared with a blank group, the rod rotating time of the mice in the low-dose group and the positive medicine group is remarkably increased (P is less than 0.01), and the rod rotating time of the mice in the medium-high dose group is increased but is not remarkable.

1.5 Pole climbing experiment of mice

The gavage compound multidimensional coenzyme Q10 effervescent tablet is continuously administrated for 30 days, the last administration is carried out for 60min, each test group of mice is placed on a clean unified organic glass rod (a rod climbing device is arranged in a water basin with the depth of 10cm and the water temperature of 15 ℃ during the test), the muscles of the mice are in a state of static tension during the rod climbing process, the time that the mice fall off the glass rod due to muscle fatigue is recorded, the time is parallelly measured for 3 times, and the average time measured by 3 times of tests is taken as the rod climbing time of the mice. The results are shown in FIG. 8. The results show that: compared with the blank group, the rod climbing time of the mice in the low-dose group is remarkably increased (P is less than 0.01), the rod climbing time of the mice in the medium-dose group is remarkably increased (P is less than 0.05), and the rod climbing time of the mice in the high-dose group and the positive drug group is increased but is not remarkable.

Experiment 2 measurement of Biochemical indicators

2.1 measurement of Biochemical indicators related to fatigue in mice

The gavage compound multi-dimensional coenzyme Q10 effervescent tablet is continuously administered for 30d, is administered for 60min at the last time, is subjected to non-load swimming for 60min, is rested for 60min, is immediately blood-taken, is killed after being anesthetized by pentobarbital injection, and is respectively taken from the liver and the gastrocnemius muscle tissue. The levels of superoxide dismutase (SOD), urea nitrogen (BUN) and blood lactic acid in serum and the liver glycogen content in liver were measured separately according to the kit instructions. The measurement result shows that: as shown in fig. 9, compared with the blank group, the serum MDA level of the mice in the low-dose group was very significantly reduced (P < 0.01), and the serum MDA levels of the mice in the medium-high dose group and the positive drug group were slightly reduced; as shown in FIG. 10, compared with the blank group, the levels of SOD in the serum of the mice in the low and medium dose groups were significantly increased (P < 0.01), and the levels of SOD in the serum of the mice in the high dose group and the positive drug group were slightly increased; as shown in fig. 11, the levels of LD in the serum of mice in the low, medium and high dose groups and the positive drug group were all significantly reduced (P < 0.01) compared to the blank group; as shown in fig. 12, the levels of BUN in the serum of mice in the low, medium, and high dose groups were significantly reduced compared to the blank group (P < 0.01); as shown in FIG. 13, liver glycogen levels were significantly increased in mice in the low, medium and high dose groups compared to the blank group (P < 0.01).

Experiment 3 histopathological analysis

The method comprises the following steps of taking gastrocnemius tissues of a mouse after exercise, soaking the gastrocnemius tissues in formalin solution for fixation, dehydrating the gastrocnemius tissues by using ethanol, carrying out paraffin embedding, carrying out section cutting, carrying out hematoxylin-eosin (HE) staining, and observing the change of the tissue structure of the gastrocnemius. The results are shown in fig. 14, the gastrocnemius muscle of the blank group of mice has different degrees of injury, irregular arrangement of muscle fiber, disorder of striation and partial inward shift of muscle cell nucleus, and the gastrocnemius muscle injury of the administration group is obviously improved, the striation is clear, and the fiber arrangement is uniform.

Experiment 4 fluorescent quantitative PCR

The gastrocnemius tissue after mouse movement was taken, total RNA was extracted, reverse transcription was performed using mRNA as a template to obtain cDNA, and the contents of AMPK and PGC-1. alpha. were quantitatively analyzed by PCR, and the primer information is shown in Table 7. The results are shown in fig. 15, which shows that the AMPK and PGC-1 α gene expression levels in gastrocnemius tissues of fatigue mice are significantly increased in the high dose group compared to the blank group, and AMPK and PGC-1 α gene expression levels are also significantly increased in the other administration groups, but are not significant.

TABLE 7 primer information

Experiment 5 Western blotting

Taking 30mg of gastrocnemius tissue of a mouse after movement, adding lysate, grinding by a tissue homogenizer, centrifuging, extracting total protein, carrying out protein quantification by a BCA method, separating proteins such as AMPK, p-AMPKP, PGC-1 alpha, Bcl-2, Bax, GAPDH and the like from the quantified protein by SDS-PAGE, taking out electrophoresis gel after electrophoresis is finished, transferring the electrophoresis gel to a membrane, successfully transferring the protein to a PVDF cellulose membrane, taking out the membrane, sealing the membrane, washing the membrane by TBST, incubating by using a specific primary antibody, washing the membrane by using TBST again, incubating by using a secondary antibody, and detecting the target protein by using a chemiluminescence kit. The results are shown in fig. 16 and 17, and the protein expressions of the AMPK/PGC-1 alpha pathway and the Bcl-2/Bax pathway are analyzed respectively, so that in the mitochondrial AMPK/PGC-1 alpha pathway, compared with the blank group, the protein expressions of AMPK, P-AMPKP and PGC-1 alpha in the high dose group are all significantly up-regulated (P is less than 0.05), and other administration groups also have an up-regulation trend; in the Bcl-2/Bax pathway, Bcl-2 is an important anti-apoptosis protein, compared with a blank group, the expression of the Bcl-2 protein in a high-dose group is obviously up-regulated (P is less than 0.05), and other administration groups are obviously up-regulated; compared with the blank group, Bax protein expression is remarkably reduced (P < 0.05) in the medium-dose group, and other administration groups also have a down-regulation trend.

And (4) conclusion:

the product is a compound effervescent solid preparation rich in vitamins, electrolytes, energy, myocardial protection and other effective components, and has effects of nourishing myocardium, supplementing energy and electrolytes, and relieving fatigue. Through various behavior experiments of mice, the combination of the determination of related biochemical indexes and the research of molecular mechanism, the compound multi-dimensional coenzyme Q10 effervescent tablet is proved to be capable of effectively enhancing exercise endurance and relieving exercise fatigue.

Claims

1. A compound multivitamin coenzyme Q10 effervescent tablet is characterized in that: the composite material comprises the following components in percentage by mass:

2. The compound multidimensional Q10 effervescent tablet of claim 1, wherein: the filler is lactose; the adhesive is PVP K30; the sweetener is stevioside; the lubricant is PEG 6000.

3. The compound multidimensional coenzyme Q10 effervescent tablet of claim 1, wherein: the alkali source is sodium bicarbonate, the acid source is tartaric acid, and the mass ratio of the tartaric acid to the sodium bicarbonate is 1-1.2: 1.

4. A preparation method of the compound multidimensional coenzyme Q10 effervescent tablet as claimed in claim 1, which is characterized in that: mixing vitamin C, nicotinamide, vitamin B6, potassium citrate, zinc gluconate, an acid source according to the mass percentage, and half of a filler, an adhesive and a sweetening agent according to the mass percentage, sieving with a 20-mesh sieve, granulating, drying, and preparing into acid granules; mixing coenzyme Q10 and polysorbate-80 in percentage by mass, grinding uniformly, adding an alkali source and half of filler, adhesive and sweetener in percentage by mass, sieving with a 20-mesh sieve, granulating, and drying to obtain alkali granules; mixing the acid granules and the alkali granules, adding the pigment and the lubricant according to the mass percentage, uniformly mixing, sieving with a 20-mesh sieve, granulating and tabletting.